Skip to main content

Table 1 Clinical characteristics, serum levels of cardiac biomarkers, and the main echocardiographic parameters of the 55 CA patients, grouped according to the presence or absence of aortic valve stenosis

From: Coexistence of aortic valve stenosis and cardiac amyloidosis: echocardiographic and clinical significance

 Patients without AS (n = 50)Patients with AS (n = 5)p-value
Clinical data
 Age (years)63.5 (58–73)69 (68–82)p = 0.055
 Male (n, %)26 (52%)3 (60%)p = 0.553
 wtTTR CA (n, %)2 (4%)1 (20%)p = 0.391
 mTTR CA (n, %)6 (12%)0 (0%)p = 0.485
 AL amyloidosis (n, %)40 (80%)4 (80%)p = 0.741
 AA amyloidosis (n, %)1 (2%)0 (0%)p = 0.909
 NYHA III-IV stage (n, %)32 (64%)5 (100%)p = 0.278
 Atrial fibrillation (n, %)11 (22%)1 (20%)p = 0.312
Laboratory data
 B-type natriuretic peptide (pg/ml)606 (234–1240)341 (77–657)p = 0.303
 Troponin T (ng/L)66 (39–104)134 (47–215)p = 0.464
Echocardiography
 Left ventricular ejection fraction (%)56 (43–63)59 (51–60)p = 0.823
 Septal wall thickness (mm)16 (13–18)17 (13–20)p = 0.578
 Inferior wall thickness (mm)15 (13–17)15 (13–16)p = 0.780
 Left ventricular end diastolic diameter (mm)42 (36–45)41 (37–42)p = 0.776
 E/e’ (Average of lateral and septal e’)20.6 (16–24)18.1 (16.9–20.6)p = 0.241
 Lateral S′5.5 (4–7)6.25 (4,25–8.3)p = 0.588
  1. AS aortic valve stenosis; wtTTR wild-type transthyretin; mTTR mutant-type transthyretin; NYHA New York Heart Association. Values are presented as medians with interquartile ranges (IQR), or as percentages. The strength of the associations was calculated with the nonparametric Mann-Whitney test or the chi-square test, as appropriate